-transparent.png){kind=logo}
Angiovist 370, a new formulation of meglumine/sodium diatrizoate, is being marketed for coronary arteriography. Angiovist 370 contains no significant calcium chelator additives, but according to manufacturer specifications may have a pH as low as 6.0. The contact times required to produce ventricular fibrillation with Angiovist 370 and with Renografin 76 were compared using a canine right coronary arteriography model. The fibrillation contact time was 32.2% longer for the Angiovist 370 than for the Renografin 76. The lower pH therefore does not appear to increase the risk of contrast media induced fibrillation. The increased contact time and safety factor with the Angiovist 370 is most likely related to the absence of calcium chelators in the formulation.
T W Morris, and
L G Sahler, and
L K Whynot, and
K Hayakawa
January 1990,
The Journal of laboratory and clinical medicine,
T W Morris, and
L G Sahler, and
L K Whynot, and
K Hayakawa
June 1988,
Investigative radiology,
T W Morris, and
L G Sahler, and
L K Whynot, and
K Hayakawa
October 1988,
Investigative radiology,
T W Morris, and
L G Sahler, and
L K Whynot, and
K Hayakawa
January 1978,
Investigative radiology,
T W Morris, and
L G Sahler, and
L K Whynot, and
K Hayakawa
January 1984,
Investigative radiology,
T W Morris, and
L G Sahler, and
L K Whynot, and
K Hayakawa
August 1971,
Radiology,
T W Morris, and
L G Sahler, and
L K Whynot, and
K Hayakawa
January 1984,
Investigative radiology,
T W Morris, and
L G Sahler, and
L K Whynot, and
K Hayakawa
May 1981,
The British journal of radiology,
T W Morris, and
L G Sahler, and
L K Whynot, and
K Hayakawa
June 1983,
Journal of the American College of Cardiology,
T W Morris, and
L G Sahler, and
L K Whynot, and
K Hayakawa
September 1988,
Investigative radiology,
